The article focuses on the need for enhanced education and training of healthcare professionals regarding the use of PCSK9 inhibitors in treating cardiovascular disease. Topics include the challenges healthcare providers face in prescribing these drugs, the importance of improving medical knowledge about new treatments, and the role of targeted educational initiatives such as e-learning and academic detailing.